In the present study, a post-hoc analysis of data from the phase 3 trial was conducted, aimed at investigating changes in the levels of PTH and bone turnover markers according to baseline BAP levels in HD patients with SHPT following upacicalcet treatment. Here, PTH is linked to Huntington disease.